Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects
This study has been completed.
Information provided by (Responsible Party):
First received: September 1, 2011
Last updated: September 13, 2012
Last verified: September 2011
The purpose of this study is to investigate the pharmacokinetic profile of ropinirole PR after single and multiple doses of the PR-formulation. It will also investigate the safety and tolerability of ropinirole PR after single and multiple doses of PR-formulation.
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Single Dose and Repeat Dose Study to Investigate the Pharmacokinetics of Ropinirole After Single and Multiple Doses of a PR-formulation in Chinese Healthy Male and Female Subjects
Primary Outcome Measures:
- Profile of Pharmacokinetics [ Time Frame: predose,1,2,3,4,6,8,10,12,14,16,18,20,22,24,36,48,72, 96,120,144,168 hours post-dose ] [ Designated as safety issue: No ]
Cmax, AUC (0-24), AUC(0-inf)
- Profile of Pharmacokinetics [ Time Frame: predose,1,2,3,4,6,8,10,12,14,16,18,20,22,24 hours after last repeated dosing ] [ Designated as safety issue: No ]
Css_max, Css_min and AUCss
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||August 2010 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Healthy adult men and women between 18 and 45 years of age, inclusive.
- Body weight >=50Kg.
- Body Mass Index (BMI) 19 - 24 kg/m2.
- No abnormality on clinical examination.
- No abnormality revealed by the clinical chemistry or haematology examination at the pre-study medical examination.
- A normal 12-lead ECG at the pre-study screening.
- Normal systolic (100-140mmHg) and diastolic (<90mmHg) blood pressure at pre-study screening.
- Written informed consent prior to admission to the study.
- Any clinically relevant abnormality identified on the screening history and physical or laboratory examination significant cardiovascular, neurological, psychiatric, haematological or renal abnormalities.
- Definite or suspected personal history or family history of adverse reactions or hypersensitivity to the study drug or to drugs with a similar chemical structure.
- History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
- The subject has received prescribed medication within 7 days prior to the first dosing day, which in the opinion of the principal medical investigator interfered with the study procedures or compromised safety.
- The subject has received over-the-counter (OTC) medicine within 48 hours prior to the first study day. Subjects who took OTC medication could still be entered into the study, if, in the opinion of the principal/co-investigator, the medication received did not interfere with the study procedures or compromised safety of the subjects.
- Abuse of alcohol, defined as an average weekly intake of greater than 21 units or an average daily intake of greater than three units. One unit is equivalent to half a pint of beer, one measure of spirits or one glass of wine.
- Positive screen for addictive drugs and tobacco.
- Participation in a trial with any drug within the 1 month before the start of the study.
- Either blood donation within the previous 3 months, or donation of a quantity of blood within the previous 12 months that would result in the subject having donated more than 1,500mL blood in a period from 12 months before this study up to and including the end of the study.
- Positive pre-study screening result for hepatitis B antigen, hepatitis C antibody and HIV-1/2 antibodies.
- Pregnancy and/or lactation;
- Female subjects of childbearing potential who are intending to become pregnant and/or are not willing to avoid pregnancy by means of barrier contraception methods (i.e. condoms or IUD) during the study from 5 days prior to screening or in the 3 months following the study.
- Female subjects with positive serum hCG test result at screening or on Days 1 of both study phases with positive urine HCG test.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01435915
|GSK Investigational Site
|Beijing, China, 100032 |
||GSK Clinical Trials
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 1, 2011
||September 13, 2012
||United States: Institutional Review Board
United States: Food and Drug Administration
China: Food and Drug Administration
China: Ethics Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 10, 2014
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs